We work with concept development, communication and relationship building to strengthen Stockholm’s competitiveness in the life sciences. Do you have ideas that you would like to realize with us? Please get in touch!
Future Health: Blood proteomics – new opportunities for precise diagnostics and disease prediction
Technological leaps during the last few years have allowed for determining protein profiles from a small drop of blood. Large-scale protein analyses of blood samples reveal new biomarkers for different diseases, indicating that blood profiling is being developed into a powerful tool for monitoring health and disease.
Blood proteomics – new opportunities for precise diagnostics and disease prediction
Recent advances in the proteomic analyses of human blood have revealed new insights and tools for monitoring disease and health. SomaLogic, who recently merged with Standard BioTools has been one of the major contributors to this rapid development. Stephen A. Williams is Chief Medical Officer at Somalogic (now Standard BioTools). He's also one of the speakers at Stockholm Science City's panel discussion Future Health, on March 19.
"I want to be an enzyme"
OKEE WILLIAMS: The life science sector is facing challenges during a three-year financial polar winter. After a period of success and optimistic growth, the landscape changed dramatically as interest rates rose. Small companies are struggling for funding with reduced investor interest, while large companies are becoming more restrained with partnerships.